Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Capital on the Frontier Measure Better Investing in Racial Equity Beyond Trade-offs Impact en las Americas New Revivalists
Local and Inclusive Climate Finance Catalytic Capital Frontier Finance Best Practices Geographies
Slack Agent of Impact Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Locavesting Entrepreneurship Gender Smart Return on Inclusion Good Jobs Creative economy Opportunity Zones Investing in place Housing New Schooled Well Being People on the Move Faith and investing Inclusive Fintech
Clean Energy Farmer Finance Soil Wealth Conservation Finance Financing Fish
Innovative Finance
Personal Finance Impact Management
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States
Subscribe
Features
Series
Themes
Community
Data
Subscribe Log In
More

Japan’s Dai-ichi Life backs biotech venture Molcure



ImpactAlpha, December 3 – Tokyo-based Molcure is developing a machine learning-powered platform to support faster drug development and the discovery of new treatments for cancers and other diseases for which there are currently no effective treatments. Life insurance company Dai-ichi is investing ¥100 million ($880,000) in the five-year-old venture.

Molcure’s platform relies on artificial intelligence and machine learning to analyze genetic materials and quickly and more cost effectively identify potential antibodies for new drug treatments. Antibody drugs target specific cells in the body, minimizing treatment side-effects. The standard process for developing these treatments is time consuming: it can take six months to identify 20,000 antibody candidates, compared to Molcure’s method of analyzing 10 million candidates in one third of the time, according to a Dai-ichi statement.

Molcure is Dai-ichi’s seventh investment since launching its impact investing initiative last October. The ¥36.3 trillion ($319.9 billion) life insurance firm has primarily backed startups working on global health initiatives, like Molcure, and access to financial services, like microfinance company Gojo & Company.

Impact investing in Japan has seen rapid growth in recent years, doubling from $337 million to $718 million since 2016.

You might also like...